Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of chronic myeloid leukemia (CML) but their use was associated with a range of serious cardiopulmonary toxicities including vascular adverse events, QT prolongation, heart failure, pleural effusion, and pulmonary arterial hypertension. Dedicated clinical management guidelines for TKI-induced toxicities are not available. This review aims to discuss TKI-associated cardiopulmonary toxicities and proposes a practical guide for their management.
CITATION STYLE
Kaddoura, R., Dabdoob, W. A., Ahmed, K., & Yassin, M. A. (2023). A practical guide to managing cardiopulmonary toxicities of tyrosine kinase inhibitors in chronic myeloid leukemia. Frontiers in Medicine. Frontiers Media SA. https://doi.org/10.3389/fmed.2023.1163137
Mendeley helps you to discover research relevant for your work.